[1] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊治指南(2011)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2011, (4): 2-25 [2] Patel V, Graves L, Lukert B. Pelvic fractures associated with long-term bisphosphonate thrapy-case report[J]. Musculoskelet Neuronal Interact, 2013(13):251-254. [3] Tella SH, Gallagher JC. Prevention and treatment of post-menopausal osteoporosis [J].J Steroid Biochem Mol Biol , 2014(142):155-170. [4] Canalis E, Giustina A, Bilezikian JP . Mechanisms of anabolic therapies for osteoporosis [J].N Engl J Med, 2007(357):905-916. [5] Yano S, Sugimoto T. Daily subcutaneous injection of teriparatide:the progress and current issues [J].Clin Calcium, 2014(24):35-43. [6] 蒋铁桥.重组人甲状旁腺素(1-34)与依降钙素对绝经后骨质疏松患者骨密度和骨代谢的影响[D].重庆医科大学, 2011. [7] 刘海蔚,高勇义,陈开宁,等.国产重组人甲状旁腺素(1-34)和降钙素治疗绝经后妇女骨质疏松症的疗效观察[J].中国妇幼保健, 2014, 29(6):934-937. [8] 杨艳,李蓬秋,朱显军,等.重组人甲状旁腺激素(1-34)和依降钙素治疗原发性骨质疏松症的随机对照研究[J].中国骨质疏松杂志, 2014, 20(2):137-141. [9] 姜金锦,罗武珍.重组人甲状旁腺激素和依降钙素在治疗绝经后骨质疏松症的对比研究[J].中国医刊, 2013, 48(1):73-74. [10] 卓苏铵.重组人甲状旁腺激素治疗绝经后骨质疏松妇女234例临床研究[J].中国妇幼保健, 2012, 27(8):1178-1180. [11] 刘爱梅.重组人甲状旁腺激素治疗绝经后骨质疏松妇女临床研究[J].当代医学, 2011, 17(32):131-133. [12] 周芸帆,杨刚毅,李伶,等.重组人甲状旁腺激素(1-34)与降钙素治疗绝经后骨质疏松临床观察[J].重庆医科大学学报, 2010, 35(2):238-240. [13] 刘忠厚.骨质疏松学[M].第一版.北京:科技出版社, 2001 :529. [14] Rosouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in health postmenopausal women:principal results from the women's health initiative randomized controlled trial[J].JAMA, 2002(288):321. [15] Sweet MG,Sweet JM,Jeremiah MP,et al.Diagnosis and treatment of osteoporosis[J].Am Fam Physician, 2009, 79(3):193-200. [16] Borgstrom F,Strom O,Marin F,et al.Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis[J].J Med Econ, 2010, 13(3):381-392. [17] Gomberg SJ,Wustrack RL,Napoli N,et al.Teriparatide,vitamin D,and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy[J].J Clin Endocrinol Metab, 2011, 96(6):1627-1632. [18] Ragucci KR,Shrader SP.Osteoporosis treatment:an evidencebased approach[J].J Gerontol Nurs, 2011, 37(7):372-373. [19] Adami S,San Martin J,Munoz-Torres M,et al.Effect of raloxifene after recombinant teriparatide treatment in postmenopausal women with osteoporosis[J].Osteoporos Int, 2008, 19(1):87-94. [20] 李丹,陈兴明,乔凤娟,等.特立帕肽与阿仑膦酸盐对比治疗骨质疏松症有效性及安全性的Meta分析[J].中国骨质疏松杂志, 2011, 17(11):997-1001.
|